Why is Johnson & Johnson stock up today?
February 28, 2026
Johnson & Johnson
JNJ · NYQ · USD
$248.43
▲ 4.96 (2.04%)
vs. prev. close $243.47
Last updated Feb 27, 2026 21:00
Intraday Chart — 5-min intervals
📊Summary
Johnson & Johnson up 2.04% — Simply Wall St. reports
- •Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?
- •Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
- •Broad market: S&P 500: -0.4%, Nasdaq: -0.9%, Dow Jones: -1.1%, Shanghai: +0.4%, Hang Seng: +0.9%, Nikkei 225: +0.2%, FTSE 100: +0.6%, Nifty 50: -1.2%, DAX: -0.0%, OMX Stockholm: +0.5%
Johnson & Johnson (JNJ) is trading notably up, at $248.43 — up 2.04% from yesterday's close of $243.47. Recent news includes "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?" and "Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors". The broader market is under pressure (S&P 500: -0.4%, Nasdaq: -0.9%, Dow Jones: -1.1%, Shanghai: +0.4%, Hang Seng: +0.9%, Nikkei 225: +0.2%, FTSE 100: +0.6%, Nifty 50: -1.2%, DAX: -0.0%, OMX Stockholm: +0.5%). Past performance does not guarantee future results.
Auto-generated · less than a minute ago
📰Recent News
1 positive1 negative6 neutral
Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?
Simply Wall St.·about 4 hours agopositiveJohnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Zacks·about 7 hours agonegativeThese Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.
Investor's Business Daily·about 8 hours agoneutralJ&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Zacks·about 15 hours agoneutral2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash
Motley Fool·about 18 hours agoneutralJohnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves
Simply Wall St.·1 day agoneutralEarly study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
PR Newswire·1 day agoneutralAre You Looking for a High-Growth Dividend Stock?
Zacks·3 days agoneutral
⚠️ Disclaimer: The information on this page is for informational purposes only and does not constitute financial advice. AI-generated summaries may be inaccurate. Always conduct your own research and consult a licensed financial advisor before making any investment decisions. Past performance is not indicative of future results.
🌐Market ContextRisk-Off 📉
S&P 500
-0.43%
Nasdaq
-0.92%
Dow Jones
-1.05%
Shanghai
+0.39%
Hang Seng
+0.95%
Nikkei 225
+0.16%
FTSE 100
+0.59%
Nifty 50
-1.25%
DAX
-0.02%
OMX Stockholm
+0.55%
Search another stock